Inflammasomes in health and disease

Inflammasomes are molecular platforms activated upon cellular infection or stress that trigger the maturation of proinflammatory cytokines such as interleukin-1β to engage innate immune defenses. The discovery of the inflammasome has led to an explosion in basic research linking the inflammasome to normal host-responses to infection as well as sterile inflammatory diseases such as type 2 diabetes, atherosclerosis and gout. Strong associations between dysregulated inflammasome activity and human heritable and acquired inflammatory diseases have also been uncovered. Collectively, these observations have ignited clinical studies to understand the role of inflammasomes in a variety of human diseases.
This two-day conference will bring together international scientists and clinicians working on the inflammasome today. Topics will range from an overview of the molecular mechanisms of inflammasome activation; the roles of IL-1, IL-18 and pyroptosis in immune defenses, novel effectors of the inflammasome and studies of the role of the inflammasome in infectious and sterile inflammatory diseases.
This conference will be a compelling mix of scientists who span basic discovery to the clinic. To encourage discussion, we will ensure a relaxed atmosphere, with plenty of time for discussion. We will particularly encourage students and postdocs to participate and present their data.
+ show speakers and program
Julie Magarian Blander, Mount Sinai School of Medicine, US
Kate Fitzgerald, University of Massachusetts, US
Doug Golenbock, University of Massachusetts, US
Akiko Iwasaki, Yale University, US
Thirumala-Devi Kanneganti, St. Jude Children's Research Hospital, US
Eicke Latz, University of Bonn, Germany
Egil Lien, University of Massachusetts, US
John MacMicking, Yale University, US
Gabriel Nunez, University of Michigan, US
Luke O'Neill, Trinity College Dublin, Ireland
Russell Vance, UC Berkeley, US

24 Jun - 25 Jun 2013

United States of America
meeting website